BioRender 아이콘

Oligodendrocyte (pre-myelinating)

Oligodendrocyte (pre-myelinating) - Editable icon of an inactivated oligodendrocyte before attachment to axon for myelination
[{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458340/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458340/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458341/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458341/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458342/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458342/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458343/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458343/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458344/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458344/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458345/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458345/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458346/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458346/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458347/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458347/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458348/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458348/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458349/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458349/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834a/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834a/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834b/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834b/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834c/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834c/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834d/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834d/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834e/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834e/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834f/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834f/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458350/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458350/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458351/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458351/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458352/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458352/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458353/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458353/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458354/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458354/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458355/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458355/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458356/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458356/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458357/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458357/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458358/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458358/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458359/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458359/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835a/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835a/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835b/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835b/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835c/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835c/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835d/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835d/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835e/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835e/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835f/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835f/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458360/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458360/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458361/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458361/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458362/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458362/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458363/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458363/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458364/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458364/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458365/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458365/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458366/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458366/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458367/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458367/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458368/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458368/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458369/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458369/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836a/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836a/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836b/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836b/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836c/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836c/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836d/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836d/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836e/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836e/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836f/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836f/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458370/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458370/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458371/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458371/5a7cc6a90d495d001444bc2d.png"}]
이 아이콘 사용하기 – 무료
가입 시 신용카드가 필요하지 않습니다.

이 아이콘은 BioRender에서 자유롭게 편집할 수 있습니다

  • 텍스트, 도형 및 기타 아이콘 추가
  • 5만 개 이상의 과학적으로 정확한 아이콘을 검색하세요
  • 모든 아이콘, 선, 라벨의 색상과 배치를 자유롭게 변경하세요
  • 어떤 용도로든 내보내거나 공유하세요
Scientist Avatars

이미 출판용 수준의 그림을 만들고 있는 400만 명 이상의 과학자들과 함께하세요

아이콘으로 몇 분 만에 완성된 그림을 만들어 보세요

  • 검색 50,000개 이상의 과학적으로 정확하고 동료 검토를 거친 아이콘 제공
  • 맞춤 설정 라벨, 도형, 추가 아이콘을 사용하여 모든 요소를 자유롭게 편집할 수 있습니다.
  • 내보내기 또는 공동 작업자와 그림 공유하기
    ‍

찾으시는 아이콘이 아닌가요? 더 많은 아이콘을 확인해 보세요.

30개 이상의 생명과학 분야에 걸친 50,000개 이상의 아이콘을 검색하세요.

search icon
arrow-right
oligodendrocyte,oiigodendroglia,glial cell,myelin,myelination,neuron,neuroglia,pns,peripheral nervous system,axon,pre-myelinating oligodendrocyte,PMO
더 보기

동의어를 검색하거나 가입하여 앱에서 아이콘을 요청해 보세요.

이미지 유형

Oligodendrocyte (pre-myelinating) icon JPEG

Oligodendrocyte (pre-myelinating) icon PNG

Oligodendrocyte (pre-myelinating) icon SVG

Oligodendrocyte (pre-myelinating) icon GIF

BioRender 아이콘 FAQ

How are scientists using the Oligodendrocyte (pre-myelinating) icon in their work?

BioRender users often use the Oligodendrocyte (pre-myelinating) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Cell Types.

이 아이콘을 BioRender 그림이나 과학 일러스트레이션에 사용할 수 있나요?

Yes, the Oligodendrocyte (pre-myelinating) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Oligodendrocyte (pre-myelinating) icon customizable in BioRender?

Most icons in BioRender, including the Oligodendrocyte (pre-myelinating) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

Can I export figures that include the Oligodendrocyte (pre-myelinating) icon for publication or presentations?

Yes, figures containing the Oligodendrocyte (pre-myelinating) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

How do I cite BioRender if I use this icon?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Is the Oligodendrocyte (pre-myelinating) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Oligodendrocyte (pre-myelinating) icon — especially those focused on Cell Types. You can search BioRender’s template library or add this icon manually to any canvas.

BioRender란 무엇인가요?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Oligodendrocyte (pre-myelinating) icon along with our library of more than 30,000 life science icons.

BioRender에서 이 아이콘 사용하기

지금 바로 전문가 수준의 과학 피규어를 만들어 보세요
antibody elements3D Phospholipid illustration

과학 콘텐츠를 찾고 계신가요?

동료 검토를 거쳐 사용하기 쉽고 무료로 제공되는 5만 개 이상의 아이콘과 템플릿을 살펴보세요.

지금 바로 찾아보세요
x icon